By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-225-2860


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. or follow ARIAD on Twitter (@ARIADPharm).

Key Statistics

Ownership: Public

Web Site: Ariad
Symbol: ARIA


Company News
9 Massachusetts Biotechs Facing Major FDA Decisions This Year 3/3/2017 6:16:42 AM
Takeda (TKPYY) Completes Acquisition Of Ariad (ARIA) 2/16/2017 9:31:56 AM
First Ariad (ARIA), Now Senator Bernie Sanders Puts This Drug Company on Notice 2/16/2017 6:01:45 AM
Ariad (ARIA) Announces Submission Of Marketing Authorization Application For Brigatinib To EMA 2/6/2017 6:34:01 AM
Ariad (ARIA) Stays Mum on Layoffs After Takeda (TKPYY)'s $5.2 Billion Takeover 1/27/2017 5:59:36 AM
A Peek Behind the Curtain of the Ariad (ARIA)-Takeda (TKPYY) Deal 1/20/2017 6:10:55 AM
After Ariad (ARIA), These 3 Drug Cancer Firms Could be Taken Out Next 1/11/2017 6:02:01 AM
How Ariad (ARIA)'s Price Hikes Resulted in a $5 Billion Payday for Investors 1/10/2017 7:04:32 AM
Takeda (TKPYY) Swallows Up Struggling Ariad (ARIA) in $5.2 Billion Deal 1/9/2017 6:17:40 AM
Ariad (ARIA)’s Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival In ALTA Study 12/7/2016 11:40:02 AM